Role of Cav2.2-mediated Signaling in Depressive Behaviors
Ying Zhou,Kimie Niimi,Weidong Li,Eiki Takahashi
DOI: https://doi.org/10.15761/imm.1000170
2015-01-01
Integrative Molecular Medicine
Abstract:Neuronal voltage-gated calcium channels (VGCCs) including Cav2.2, mediate the mechanisms involved in the presynaptic release of neurotransmitters. The role of Cav2.2 in neural circuits underlying depression remains poorly understood. In this study, intracerebroventricular injection of the Cav2.2 inhibitor ω-conotoxin GVIA (5 pg/side) in mice increased depression-like behavior in the forced swimming and tail suspension tests. These results suggest that Cav2.2-mediated signaling plays a role in depressive behaviors. Introduction Voltage-gated Ca2+ (Cav) channels play an important role in regulating diverse neuronal functions attributed to elevated intracellular Ca2+ concentrations [1,2]. Cav channels are molecular complexes comprising α1, β, α2-δ, and γ subunits [1]. The α1 subunit is essential for channel function and determines fundamental channel properties [1]. Genes encoding 10 pore-forming α1 subunits and several splice variants have been identified and characterized [3]. At the presynaptic terminal, Cav2.2 (N type) channels mediate Ca2+-dependent exocytotic release of neurotransmitters [4]. Ca2+ influx via these channels triggers neurotransmitter release in a cooperative process with other components of the vesicle fusion machinery [5]. Given the pivotal role of Ca2+ channels in controlling neurotransmitter release, defects in the expression, localization, structure, or modulation of presynaptic Ca2+ channels may result in aberrant synaptic signaling, leading to various patterns of neural network dysfunction. Cav2.2 channels have been reported to influence the release of dopamine [DA; 6–8], serotonin [5-HT; 9], glutamate [10], gamma-aminobutyric acid [11], acetylcholine [12], and norepinephrine [NE; 13] from central neurons. In terms of clinical relevance, imbalances of neurotransmitters are strongly associated with depression [14]. According to the monoamine hypothesis, depression can be ascribed to deficits in the major monoamine neurotransmitters (DA, 5-HT, and NE). As Cav2.2 channels are involved in the regulation of neurotransmitter release, administration of a Cav2.2 blocker is expected to result in depressive behavior. In mice that received intracerebroventricular (i.c.v.) injections of ω-conotoxin GVIA, a Cav2.2 inhibitor, baseline levels of DA and 5-HT were reduced in the striatum and frontal cortex [15]. The Cav2.2 inhibitor also induced depressive behavior, as measured by the forced swimming test [16] and tail suspension test [17]. In the present study, the relationship between Cav2.2-mediated signaling and depression was investigated further. Mice were treated with i.c.v. injections of ω-conotoxin GVIA, and depression was assessed using forced swimming and tail suspension tests. Materials and methods Mice All animal procedures were approved by the Animal Experiments Committee of Shanghai Jiao Tong University and RIKEN. C57BL/6J mice were provided by Charles River Japan (Kanagawa, Japan). The mice were given free access to water and food pellets (CRF-1; Oriental Yeast Co. Ltd., Tokyo, Japan) and housed under a 12/12-h light/dark cycle (lights on from 08:00 to 20:00) at 23 ± 1°C and 55 ± 5% humidity. We used separate groups of 2-month-old male mice for each of the behavioral tests. All experiments were conducted by investigators blinded to the treatment conditions at light phase. Infusion For the infusion studies, the Cav2.2 blocker, ω-conotoxin GVIA (100 pg/μL, Peptide Institute, Osaka, Japan) was dissolved in saline (vehicle). The drug dose was determined based on a previous report [15,18,19]. Non-treated mice received an equivalent volume of vehicle. Under anesthesia and using standard stereotaxic procedures, stainlesssteel guide cannulae (22-gauge) were implanted into the lateral ventricle (posterior to bregma, -0.34 mm; lateral to midline, ±0.9 mm; ventral from the dura, −2.3 mm), and mice were allowed to recover for at least 1 week following surgery. The mice were briefly anesthetized with isoflurane to facilitate insertion of the injection cannula (26-gauge). Infusion into the lateral ventricle (0.1 μL/side) was accomplished at a rate of 0.05 μL/min 30 min before behavioral testing. The injection cannula was left in place for 2 min following infusion. Correspondence to: Eiki Takahashi, DVM, PhD, Research Resources Center, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako, Saitama, 351-0198, Japan, Tel: +81-48-467-5871; Fax: +81-48-467-9692, E-mail: etakahashi@brain.riken.jp